Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau; Shaji K. Kumar; Jesús San Miguel; Faith Davies; Elena Zamagni; Nizar Bahlis; Heinz Ludwig; Joseph Mikhael; Evangelos Terpos; Fredrik Schjesvold; Thomas Martin; Kwee Yong; Brian G.M. Durie; Thierry Facon; Artur Jurczyszyn; Surbhi Sidana; Noopur Raje; Niels van de Donk; Sagar Lonial; Michele Cavo; Sigurdur Y. Kristinsson; Suzanne Lentzsch; Roman Hajek; Kenneth C. Anderson; Cristina João; Hermann Einsele; Pieter Sonneveld; Monika Engelhardt; Rafael Fonseca; Annette Vangsted; Katja Weisel; Rachid Baz; Vania Hungria; Jesus G. Berdeja; Fernando Leal da Costa; Angelo Maiolino; Anders Waage; David H. Vesole; Enrique M. Ocio; Hang Quach; Christoph Driessen; Joan Bladé; Xavier Leleu; Eloisa Riva; Peter Leif Bergsagel; Jian Hou; Wee Joo Chng; Ulf Henrik Mellqvist; Dominik Dytfeld; Jean Luc Harousseau; Hartmut Goldschmidt; Jacob Laubach; Nikhil C. Munshi; Francesca Gay; Meral Beksac; Luciano J. Costa; Martin Kaiser; Parameswaran Hari; Mario Boccadoro; Saad Z. Usmani; Sonja Zweegman; Sarah Holstein; Orhan Sezer; Simon Harrison; Hareth Nahi; Gordon Cook; Maria Victoria Mateos; S. Vincent Rajkumar; Meletios A. Dimopoulos; Paul G. Richardson

doi:10.1016/S1470-2045(20)30756-7

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Philippe Moreau
, Shaji K. Kumar
, Jesús San Miguel
, Faith Davies
, Elena Zamagni
, Nizar Bahlis
, Heinz Ludwig
, Joseph Mikhael
, Evangelos Terpos
, Fredrik Schjesvold
, Thomas Martin
, Kwee Yong
, Brian G.M. Durie
, Thierry Facon
, Artur Jurczyszyn
, Surbhi Sidana
, Noopur Raje
, Niels van de Donk
, Sagar Lonial
, Michele Cavo

Sigurdur Y. Kristinsson, Suzanne Lentzsch, Roman Hajek, Kenneth C. Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafael Fonseca, Annette Vangsted, Katja Weisel, Rachid Baz, Vania Hungria, Jesus G. Berdeja, Fernando Leal da Costa, Angelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloisa Riva, Peter Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf Henrik Mellqvist, Dominik Dytfeld, Jean Luc Harousseau, Hartmut Goldschmidt, Jacob Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksac, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah Holstein, Orhan Sezer, Simon Harrison, Hareth Nahi, Gordon Cook, Maria Victoria Mateos, S. Vincent Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson

School of Medicine

University Hospital Hotel-Dieu
Mayo Clinic Rochester, MN
University of Navarra
New York University
University of Bologna
University of Calgary
Klinik Ottakring
Translational Genomics Research Institute
National and Kapodistrian University of Athens
University of Oslo
University of California at San Francisco
University College London
Cedars-Sinai Medical Center
Université de Lille
Jagiellonian University Medical College
Stanford University
Massachusetts General Hospital
Vrije Universiteit Amsterdam
Emory University
University of Iceland
Columbia University
University of Ostrava
Dana-Farber Cancer Institute
Clinical Centre Champalimaud
University of Würzburg
Erasmus University Rotterdam
University of Freiburg
Mayo Clinic Scottsdale, AZ
University of Copenhagen
University of Hamburg
Moffitt Cancer Center
Clinica San Germano
Sarah Cannon Research Institute
University of Alabama at Birmingham
Universidade Federal do Rio de Janeiro
Norwegian University of Science and Technology
Hospital Universitario Marques de Valdecilla
University of Melbourne
Kantosspital St Gallen
University Hospital Clinic
CHU de Poitiers
Universidad de la República
British Hospital Montevideo
Changzheng Hospital
National University of Singapore
South Elfsborg Hospital
University of Medical Sciences Poznan
University Hospital
Heidelberg University
Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino
Ankara University
Levine Cancer Institute
Divisions of Molecular Pathology and Cancer Therapeutics
Medical College of Wisconsin
University of Nebraska Medical Center
Memorial Sisli Hastanesi
Peter Maccallum Cancer Centre
Karolinska Institutet
Leeds Teaching Hospitals NHS Trust
Universidad de Salamanca

Research output: Contribution to journal › Review article › peer-review

265 Scopus citations

Abstract

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

Original language	English
Pages (from-to)	e105-e118
Journal	The Lancet Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(20)30756-7
State	Published - Mar 2021

Access to Document

10.1016/S1470-2045(20)30756-7

Cite this

Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., ... Richardson, P. G. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22(3), e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

@article{8b39b9a9852e4d1794e37f6be46f8218,

title = "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group",

abstract = "This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.",

author = "Philippe Moreau and Kumar, \{Shaji K.\} and \{San Miguel\}, Jes{\'u}s and Faith Davies and Elena Zamagni and Nizar Bahlis and Heinz Ludwig and Joseph Mikhael and Evangelos Terpos and Fredrik Schjesvold and Thomas Martin and Kwee Yong and Durie, \{Brian G.M.\} and Thierry Facon and Artur Jurczyszyn and Surbhi Sidana and Noopur Raje and \{van de Donk\}, Niels and Sagar Lonial and Michele Cavo and Kristinsson, \{Sigurdur Y.\} and Suzanne Lentzsch and Roman Hajek and Anderson, \{Kenneth C.\} and Cristina Jo{\~a}o and Hermann Einsele and Pieter Sonneveld and Monika Engelhardt and Rafael Fonseca and Annette Vangsted and Katja Weisel and Rachid Baz and Vania Hungria and Berdeja, \{Jesus G.\} and \{Leal da Costa\}, Fernando and Angelo Maiolino and Anders Waage and Vesole, \{David H.\} and Ocio, \{Enrique M.\} and Hang Quach and Christoph Driessen and Joan Blad{\'e} and Xavier Leleu and Eloisa Riva and Bergsagel, \{Peter Leif\} and Jian Hou and Chng, \{Wee Joo\} and Mellqvist, \{Ulf Henrik\} and Dominik Dytfeld and Harousseau, \{Jean Luc\} and Hartmut Goldschmidt and Jacob Laubach and Munshi, \{Nikhil C.\} and Francesca Gay and Meral Beksac and Costa, \{Luciano J.\} and Martin Kaiser and Parameswaran Hari and Mario Boccadoro and Usmani, \{Saad Z.\} and Sonja Zweegman and Sarah Holstein and Orhan Sezer and Simon Harrison and Hareth Nahi and Gordon Cook and Mateos, \{Maria Victoria\} and Rajkumar, \{S. Vincent\} and Dimopoulos, \{Meletios A.\} and Richardson, \{Paul G.\}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = mar,

doi = "10.1016/S1470-2045(20)30756-7",

language = "English",

volume = "22",

pages = "e105--e118",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "3",

}

Moreau, P, Kumar, SK, San Miguel, J, Davies, F, Zamagni, E, Bahlis, N, Ludwig, H, Mikhael, J, Terpos, E, Schjesvold, F, Martin, T, Yong, K, Durie, BGM, Facon, T, Jurczyszyn, A, Sidana, S, Raje, N, van de Donk, N, Lonial, S, Cavo, M, Kristinsson, SY, Lentzsch, S, Hajek, R, Anderson, KC, João, C, Einsele, H, Sonneveld, P, Engelhardt, M, Fonseca, R, Vangsted, A, Weisel, K, Baz, R, Hungria, V, Berdeja, JG, Leal da Costa, F, Maiolino, A, Waage, A, Vesole, DH, Ocio, EM, Quach, H, Driessen, C, Bladé, J, Leleu, X, Riva, E, Bergsagel, PL, Hou, J, Chng, WJ, Mellqvist, UH, Dytfeld, D, Harousseau, JL, Goldschmidt, H, Laubach, J, Munshi, NC, Gay, F, Beksac, M, Costa, LJ, Kaiser, M, Hari, P, Boccadoro, M, Usmani, SZ, Zweegman, S, Holstein, S, Sezer, O, Harrison, S, Nahi, H, Cook, G, Mateos, MV, Rajkumar, SV, Dimopoulos, MA & Richardson, PG 2021, 'Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group', The Lancet Oncology, vol. 22, no. 3, pp. e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

TY - JOUR

T1 - Treatment of relapsed and refractory multiple myeloma

T2 - recommendations from the International Myeloma Working Group

AU - Moreau, Philippe

AU - Kumar, Shaji K.

AU - San Miguel, Jesús

AU - Davies, Faith

AU - Zamagni, Elena

AU - Bahlis, Nizar

AU - Ludwig, Heinz

AU - Mikhael, Joseph

AU - Terpos, Evangelos

AU - Schjesvold, Fredrik

AU - Martin, Thomas

AU - Yong, Kwee

AU - Durie, Brian G.M.

AU - Facon, Thierry

AU - Jurczyszyn, Artur

AU - Sidana, Surbhi

AU - Raje, Noopur

AU - van de Donk, Niels

AU - Lonial, Sagar

AU - Cavo, Michele

AU - Kristinsson, Sigurdur Y.

AU - Lentzsch, Suzanne

AU - Hajek, Roman

AU - Anderson, Kenneth C.

AU - João, Cristina

AU - Einsele, Hermann

AU - Sonneveld, Pieter

AU - Engelhardt, Monika

AU - Fonseca, Rafael

AU - Vangsted, Annette

AU - Weisel, Katja

AU - Baz, Rachid

AU - Hungria, Vania

AU - Berdeja, Jesus G.

AU - Leal da Costa, Fernando

AU - Maiolino, Angelo

AU - Waage, Anders

AU - Vesole, David H.

AU - Ocio, Enrique M.

AU - Quach, Hang

AU - Driessen, Christoph

AU - Bladé, Joan

AU - Leleu, Xavier

AU - Riva, Eloisa

AU - Bergsagel, Peter Leif

AU - Hou, Jian

AU - Chng, Wee Joo

AU - Mellqvist, Ulf Henrik

AU - Dytfeld, Dominik

AU - Harousseau, Jean Luc

AU - Goldschmidt, Hartmut

AU - Laubach, Jacob

AU - Munshi, Nikhil C.

AU - Gay, Francesca

AU - Beksac, Meral

AU - Costa, Luciano J.

AU - Kaiser, Martin

AU - Hari, Parameswaran

AU - Boccadoro, Mario

AU - Usmani, Saad Z.

AU - Zweegman, Sonja

AU - Holstein, Sarah

AU - Sezer, Orhan

AU - Harrison, Simon

AU - Nahi, Hareth

AU - Cook, Gordon

AU - Mateos, Maria Victoria

AU - Rajkumar, S. Vincent

AU - Dimopoulos, Meletios A.

AU - Richardson, Paul G.

PY - 2021/3

Y1 - 2021/3

N2 - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

AB - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

UR - https://www.scopus.com/pages/publications/85101689680

U2 - 10.1016/S1470-2045(20)30756-7

DO - 10.1016/S1470-2045(20)30756-7

M3 - Review article

C2 - 33662288

AN - SCOPUS:85101689680

SN - 1470-2045

VL - 22

SP - e105-e118

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Abstract

Access to Document

Other files and links

Fingerprint

Cite this